Stockscreener 앱 받기
2.15
1.15%
-0.025
시간 외 거래:
2.15
전일 마감가:
$2.175
열려 있는:
$2.13
하루 거래량:
29,640
Relative Volume:
0.03
시가총액:
$3.72M
수익:
-
순이익/손실:
$-2.77M
주가수익비율:
-0.8124
EPS:
-2.6464
순현금흐름:
$-2.69M
1주 성능:
-5.70%
1개월 성능:
-16.99%
6개월 성능:
-26.50%
1년 성능:
-50.97%
1일 변동 폭
$2.13
$2.28
1주일 범위
$2.055
$2.3976
52주 변동 폭
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.15 | 3.79M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc 주식(XRTX)의 최신 뉴스
XORTX Therapeutics appoints Mika Grasso as co‑CEO - MSN
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange - marketscreener.com
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO - marketscreener.com
XORTX Therapeutics Providing Corporate Update and Appoints Mika Grasso as Co-CEO - marketscreener.com
XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO - Stock Titan
A 28-year-old co-CEO and XORTX's $700M gout push in the US - Stock Titan
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange - The Manila Times
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | Associated Press | syndication news - Enidnews.com
XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture - Stock Titan
XORTX drops TSX Venture listing to reduce costs, focus on gout drug - Stock Titan
XORTX Therapeutics Company Profile & Introduction - Moomoo
XRTX Stock Chart | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics (XRTX) Slides Over 3% as Biotech Stock Tests Key Support LevelsBreakout Stock Alerts - newsline.com
XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading SessionSkew Index - thelegaladvocate.com
XORTX Therapeutics (XRTX) Edges Higher as Stock Holds Above Key SupportAnalyst Upgrade Stocks - newsline.com
XORTX Therapeutics (XRTX) Gains 1.27% as Shares Test Key Resistance LevelFund Manager Survey - newsline.com
XRTX News | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics Q1 2024 Earnings: Steep EPS Miss Highlights Pre‑Revenue Biotech HurdlesGuidance Upgrade Report - newsline.com
XORTX Therapeutics Raises US$5 Million Via Public Offering - marketscreener.com
XORTX Announces Closing of US$5 Million Public Offering - markets.businessinsider.com
XORTX Therapeutics (NASDAQ: XRTX) closes US$5M share and pre-funded warrant deal - Stock Titan
XORTX raises US$5M, earmarks US$2.5M for investor marketing - Stock Titan
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering - The Manila Times
XORTX Therapeutics Inc.Common Shares (NQ: XRTX - FinancialContent
XORTX Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XORTX Therapeutics Inc expected to post a loss of C$1.64 a shareEarnings Preview - TradingView
Here are the top movers in Friday's session. - ChartMill
XORTX (NASDAQ: XRTX) raises ~$4.7M via share sale and pre-funded warrants - Stock Titan
XRTX Announces Public Offering of Shares - GuruFocus
XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9% - marketscreener.com
XORTX (NASDAQ: XRTX) prices US$5M public equity and warrant deal - Stock Titan
Xortx announces US$5 million public offering - marketscreener.com
XORTX Announces US$5 Million Public Offering - The Manila Times
XORTX Announces US$5 Million Public Offering | Associated Press | syndication news - Enidnews.com
[EFFECT] XORTX Therapeutics Inc. SEC Filing - Stock Titan
Kidney drug developer XORTX prices US$5M Nasdaq share sale - Stock Titan
XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold - The Globe and Mail
XORTX (NASDAQ: XRTX) estimates $4.1M equity, above Nasdaq minimum - Stock Titan
1.8M-share offering — XORTX Therapeutics (NASDAQ: XRTX) files F-1 amendment - Stock Titan
XRTX XORTX Therapeutics posts far wider Q1 2024 loss than estimates, shares fall 1.85% amid elevated RD spending.Balance Sheet - newser.com
XORTX shareholders approve up-to-5-for-1 share consolidation to meet Nasdaq rules - MSN
XORTX Therapeutics (XRTX) Stock: Pricing Efficiency Review | Q1 2024: Earnings Fall ShortAnalyst Recommended Stocks - Newser
XORTX Therapeutics (NASDAQ: XRTX) registers up to 2.2M shares; $4.7M estimated proceeds - Stock Titan
XORTX Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
Xortx Therapeutics Inc (XRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):